Arthneeti
Molbio Diagnostics Ltd Q2 FY27 results are out (Jul–Sep 2026) →Revenue ₹259 Cr +159.8% YoYSee revenue, profit and what management said. You are viewing Q1 FY27.
MD

Molbio Diagnostics Ltd

Q1 FY27Healthcare Equipment & Supplies

Molbio Diagnostics Q1 FY27: Capex ₹72 Cr

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Revenue
₹408Cr
Net profit
₹53Cr
Margin
24.63%

What the Q1 FY27 call signalled

2 of 3 strong

RevenueGood growth
MarginMargins steady
CapexCapex planned
Price₹1,288
Market cap₹16.6K Cr
P/E66.4

The short version

Expecting roughly 25% top-line growth for FY27, driven by increasing device and test kit sales. - Test kit volumes are increasing significantly, with Q1 FY27 kits volumes higher than Q4 FY26, indicating strong recurring revenue growth. - Device sales expected to remain steady, historically ranging between 2,200 to 2,600 units annually. - Export business ramping up aggressively, expanding in over 90 countries including LMICs and developed markets (Europe, US). - New product rollouts such as Truenat HPV and OptraScan (recent U.S. Molbio Diagnostics is targeting roughly 25% top-line growth for FY27.

From Molbio Diagnostics Ltd's Q1 FY27 earnings-call transcript · updated 18 Sept 2026.

Revenue & Sales Performance

Good growth
  • Expecting roughly 25% top-line growth for FY27, driven by increasing device and test kit sales.
  • Test kit volumes are increasing significantly, with Q1 FY27 kits volumes higher than Q4 FY26, indicating strong recurring revenue growth.
  • Device sales expected to remain steady, historically ranging between 2,200 to 2,600 units annually.
  • Export business ramping up aggressively, expanding in over 90 countries including LMICs and developed markets (Europe, US).
  • New product rollouts such as Truenat HPV and OptraScan (recent U.S. FDA approval) expected to open up new large revenue streams over the medium term.
  • Capacity utilization currently at ~58% for test kits and ~42% for devices; automation capex will double revenue capacity with minimal new investment.

2 more points from Molbio Diagnostics Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Molbio Diagnostics Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • ₹200 crores raised in the IPO for automation and infrastructure.
  • ₹72 crores allocated for automation to increase efficiency and capacity, enabling up to 2x revenue growth without major new capex.
  • ₹105 crores planned for building an integrated R&D center in Bangalore to consolidate over 150 scientists and support staff.
  • No major capex expected for expanding manufacturing capacity; current utilization is 58% for test kits and 42% for devices.

2 more points from Molbio Diagnostics Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Healthcare Equipment & Supplies

Ranked on what management guided this quarter

Guidance-ranked
1OSEL Devices
Rev 1Mar 3
2Avience Biomedicals
Rev 1Mar 3
3
Rev 2Mar 3
4
Rev 3Mar 1
5
Rev 3Mar 2
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Molbio Diagnostics Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Relevant insights from the call include: - Export orders experienced some deferrals, e.g., a certain order shifted from FY26 to Q1 FY27, contributing to fluctuations in export revenue. - Export business is stabilizing across 90 countries with ongoing registrations, indicating a growing international order pipeline.

2 more points from Molbio Diagnostics Ltd's call on order book

Create a free account to keep reading this call

Molbio Diagnostics Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Molbio Diagnostics Ltd Q1 FY27 results — key figures

Molbio Diagnostics Ltd Q1 FY27 reported results vs year-ago quarter, ₹ crore
₹ CrQ1 FY27Q4 FY26QoQ
Revenue408561-27.2%
Operating profit (EBITDA)101159-36.6%
Operating margin24.63%28.31%-3.7 pp
Profit before tax76132-42.4%
Net profit (PAT)5396-45%
EPS (₹)5.218.06-35.4%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹259 Cr, net profit ₹8 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Molbio Diagnosti's management said in earlier quarters

Others in Healthcare Equipment & Supplies this season

  • Nureca (Q1 FY27)

    Revenue from Operations for Q1 FY'27: ₹40.3 Cr . Key investor presentation takeaways from Nureca's Q1 FY27 investor presentation — and how it ranks against sect

  • Avience Biomedicals (Q1 FY27)

    New manufacturing facility has capacity to support peak revenue of around ₹250–265 crore, subject to product mix and approvals. Key concall takeaways from…

  • Fischer Medical (Q1 FY27)

    The provided pages of the investor presentation do not contain any specific revenue, sales, or volume figures for the quarter, nor details on year-on-year…

  • QMS Medical (Q1 FY27)

    Contract renewals historically exhibit a 60-70% roll-over rate annually, ensuring revenue visibility from existing clients. Key concall takeaways from QMS…

Compare:vs Poly Medicurevs Sahajanand Medivs Fischer Medical

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Molbio Diagnostics Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Molbio Diagnostics Ltd Q1 FY27 results?

Expecting roughly 25% top-line growth for FY27, driven by increasing device and test kit sales. - Test kit volumes are increasing significantly, with Q1 FY27 kits volumes higher than Q4 FY26, indicating strong recurring revenue growth. - Device sales expected to remain steady, historically ranging between 2,200 to 2,600 units annually. - Export business ramping up aggressively, expanding in over 90 countries including LMICs and developed markets (Europe, US). - New product rollouts such as Truenat HPV and OptraScan (recent U.S. Molbio Diagnostics is targeting roughly 25% top-line growth for FY27.

What is Molbio Diagnostics Ltd share price analysis?

Molbio Diagnostics Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 66.4 with a market cap of ₹16,574 Cr. Investors should review the full earnings analysis for detailed insights.

Is Molbio Diagnostics Ltd planning capital expenditure?

₹200 crores raised in the IPO for automation and infrastructure.

Keep Molbio Diagnostics Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.